PDB5 Statin is a Reasonable Treatment Option for Patients With Polysystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials  by Gao, L. & Li, S.C.
PCN33
HEALTH RELATED QUALITY OF LIFE IN POST-OPERATIVE BREAST CANCER
PATIENTS
Jo MW
University of Ulsan College of Medicine, Seoul, South Korea
OBJECTIVES: This study was conducted to evaluate health related quality of life
(HRQOL) in post-operative breast cancer patients of Korea.METHODS: A consecu-
tive series of patients with breast cancer who visited to one university hospitals in
Seoul after operation as a primary treatment from Feb to Mar 2012 were recruited.
Their HRQOL was assessed using EQ-5D, SF36 and FACT-B. General and clinical
information was obtained from the interviews and medical chart reviews. HRQOL
was analyzed on general and clinical information of them. RESULTS: Among 487
patients with breast cancer, 487 patients complete the questionnaire. All study
participants were female and their mean age was 52.5. In the aged, low education
group, and divorced or bereaved people, their HRQOL were lower than those of the
other groups, respectively. All correlation coefficients between EQ-5D index, 8
scales of SF-36 and FACT-B score were statistically significant (p0.001,
respectively). CONCLUSIONS: This study showed the HRQOL of post-operative
breast cancer patients in South Korea.
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DIABETES MELLITUS
Zhao Y1, Campbell C2, Fonseca V2, Shi L2
1Saint Joseph College, Hartford, CT, USA, 2Tulane University, New Orleans, LA, USA
OBJECTIVES: To identify risk factors among veterans with type 2 diabetes mellitus
(T2DM) initiated on new anti-hyperglycemic treatments.METHODS: Electronic re-
cords were obtained for adults with at least 2 records of T2DM diagnosis (ICD-9-CM
codes: 250.xx except for 250.x1 and 250.x3) from the VISN 16 data warehouse from
January 1, 2004 to September 1, 2010. The first dispense date of a new antihyper-
glycemic agent (index drug) was defined as the index date. The hypoglycemia
group and control group were identified by hypoglycemia (ICD-9-CM codes: 250.8,
251.0, 251.1 and 251.2) during index-treatment period and no hypoglycemia during
one-year post-index period, respectively. Select patients had no records of hypo-
glycemia, cardiovascular disease, or microvascular complications during the one-
year pre-index period. A logistic regressionmodelwas employed to identify the risk
factors for post-index hypoglycemia. RESULTS: Among 44,261 patients (hypogly-
cemia: n761, control: n43,500), the incidence rate of hypoglycemia events was
3.57 per 100 patient-years. The hypoglycemia group was more likely to have renal
disease, mental disorder, substance abuse, and tobacco use. More patients under
poor glycemic control (HbA1c7%) was found in the hypoglycemia group (91.4%)
compared to those in the control group (87.8%) (p0.0043). The hypoglycemia
group used significantly more health care resources at baseline than the control
group [hospitalization (14.6% vs. 7.2%, p0.0001); emergency room (32.7% vs. 19.3%,
p0.0001); outpatient visits on average (13.33 vs. 7.34, p0.0001)]. The hypoglyce-
mia group wasmore likely to use insulin at baseline or initiated with insulin as the
index drug. Insulin use (baseline or index) and renal disease were top risk factors
(odds ratio2) in the logistical model. CONCLUSIONS: Among veterans with
T2DM, the hypoglycemia group was in general sicker than the control group. Sub-
populations who were insulin user or with comorbid renal disease were even at
higher risk for hypoglycemia.
PDB2
EPIDEMIOLOGY, PATIENT BURDEN AND RELATED COSTS OF OBESITY IN INDIA
Wojciechowski P1, Metz L2, Mapari J2, Jain M3, Neoh K4, Caban A1, Gaweska M1, Gomulka
A1, Plisko R1, Wladysiuk M1, Rys P1
1HTA Consulting, Krakow, Poland, 2Johnson & Johnson Medical Asia-Pacific, Singapore,
Singapore, 3Johnson & Johnson Medical, New Delhi, India, 4Johnson & Johnson Medical Asia-
Pacific, Petaling Jaya, Malaysia
OBJECTIVES: Recent changes in lifestyle has triggered an increased prevalence of
obesity even in developing countries such as India. Obesity is known to be corre-
lated with increased risk of Type 2 Diabetes and Cardiovascular diseases. The
burden of obesity may be underestimated as Indians are at higher risk of comor-
bidities with comparatively lower BMI. The aim of our research was to assess the
epidemiology and burden of obesity in India.METHODS: International and Indian
medical databases (MEDLINE, EMBASE, dmri.in) as well as archives of Indian med-
ical journals (nmji.in, japi.in) were searched to collect information regarding epi-
demiology and burden of obesity. RESULTS: Our search retrieved 27 relevant pub-
lications. The prevalence of obesity among Indian adultswas setting-dependent. In
rural areas, obesity was diagnosed in 5.1% - 8.5% and 5.2% - 12.7% of men and
women, respectively. In urbanized regions 15.9% - 38.2% of men and 23.5% - 47.6%
of women were obese. Evidence for burden of obesity was sparse and based on
single trials reporting increased risk of diabetes (RR  8.45 [1.09; 65,36]), hyperten-
sion (RR  2.19 [1.16; 4,13]) and breast cancer (RR  2.27 [1.28; 4,01]) in obese as
compared to normal-weight patients. No correlation between overweight and ex-
cessive risk of death was found. Obesity and diabetes place a significant economic
burden on society mainly due to indirect costs including productivity loss, de-
creased household earnings and higher dependence on welfare. Indeed, 15%-25%
of household income is spent on treatment of diabetic patients in India, and with
the rising incidence, this will only worsen over time. CONCLUSIONS: Obesity and
diabetes burden the constrained health care system of India and the entire society,
leading to lost productivity and decreased household incomes. With the rising
prevalence, this burden will only worsen unless effective measures to address the
same are put in place.
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OBJECTIVES: Obesity is a cause of more deaths than malnutrition in most high/
middle income countries. Asians are especially likely to accumulate intra-abdom-
inal fat increasing a risk of obesity-related comorbidities. The aim of our research
was to assess the epidemiology and burden of obesity in China. METHODS: Inter-
national and Chinese medical databases (MEDLINE, EMBASE, wanfangdata.com,
cqvip.com, cnki.net, docin.com, wenku.baidu.com) were searched to collect infor-
mation regarding epidemiology and burden of obesity. RESULTS: Our search re-
trieved 34 relevant publications. The prevalence of obesity among Chinese adults
oscillated between 2.7% and 13.1% in rural and urban areas, respectively. Most
often the overall prevalence in combined rural andurban populationswas reported
in the range between 4% and 11.6%. Epidemiological trends reveal an alarming
increase in the prevalence of obesity among Chinese adults, which increased from
0.3%-2.9% in the late ’80s and early ’90s, to 3%-11.4 in the first decade of 21st
century. This increase translates into a growing number of obesity-related dis-
eases, such as hypertension reaching 18.8% in 2002 and type 2 diabetes (T2DM)
affecting 2.6% population. In Beijing, hypertension and T2DM were 25% and 7.7%,
respectively. In the Chinese population, severe obesity increases the risk of death
by 29%. The growing costs of obesity is a burden on health care. The estimated
direct costs of obesity in the year 2000 were nearly $6 billion, while the indirect
costs associated with loss of productivity exceeded $43 billion, corresponding to
0.48% and 3.58% of gross national product (GNP), respectively. The estimates for
productivity loss are rising dramatically to $106 billion in 2025,which represents an
increase to 8.73% of China’s GNP. CONCLUSIONS: The growing rates of obesity and
obesity-related comorbidities is a rapidly growing economic burden on the Chinese
health care system and calls for prevention and treatment strategies.
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OBJECTIVES: To develop and validate simple, sensitive and selective HPLCmethod
for determination of glipizide in human plasma. METHODS: Liquid-liquid extrac-
tion method was used to extract glipizide from the human plasma samples. Chro-
matographic separation of glipizide was achieved using C18column (ZORBAX ODS
4.6 X 150mm). The mobile phase was comprised of 0.01 M potassium dihydrogen
phosphate and acetronitrile (65:35, v/v) adjusted to pH 4.25 with glacial acetic acid.
The analysis was run at a flow rate of 1.5 ml/min with an injection volume was 20
L. The UV detector was operated at 275 nm. The proposed method was validated
aswith respect to selectivity, linearity, accuracy, precision, recovery, limit of quan-
tification (LOQ) and stability. RESULTS: The calibration curve was linear over a
concentration range of 50 – 1600 ng/mL. Intra-day and inter-day precision and
accuracy values were below 15%. The limit of quantification was 50 ng/mL and the
mean recovery was above 98%. Freeze-thaw, short-term, long-term and post-pre-
parative stability studies showed that glipizide in plasma sample was stable.
CONCLUSIONS: A rapid, simple, selective and sensitive HPLC method for determi-
nation of glipizide in human plasma was successfully developed. The method
showed good recovery, accuracy and precision. The method can be successfully
applied to in pharmacokinetics and bioequivalence studies to quantify glipizide in
plasma samples.
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OBJECTIVES: To date no consensus has been reached on whether to administer
statin to patients with Polycystic Ovary Syndrome (PCOS) routinely. Therefore, we
conduct a meta-analysis to synthesize the existing literatures regarding therapeu-
tic effects of statins on PCOS. METHODS: A comprehensive literature search was
performed using terms such as polycystic ovary syndrome, ovary polycystic dis-
ease, PCOS, hyperandrogaenemia; exposures including statin, simvastatin, atorv-
astatin, rosuvastatin, lovastatin, mevastatin, pravastatin, lipidemic-modulating
drugs, lipid lowering drugs, and testosterone; study types including randomized
controlled trails or studies or randomized in the following bibliographic databases
from inception to 30 Sep 2011: Medline, Embase, Cochrane Controlled Trials Reg-
ister and Biological Abstracts. Identified reference lists were checked manually to
retrieve related papers. RESULTS: In total, four RCTs were included. Three of four
studies were double-blinded while none reported whether of the data was ana-
lyzed using Intention-to-Treat analysis. Serum total testosterone and lipid profiles
were included as investigation outcomes in all four studies. Differences in reducing
serum total testosterone were observed when comparing statin with placebo (Std
MD -3.03, 95%CI -5.85-0.22, P0.03) or statinmetformin with metformin (Std
MD-1.07, 95%CI: -2.06-0.07, P0.04). Heterogeneitieswere detected in both com-
parisons (I296% and 88% respectively). Meanwhile, statinwasmore effective than
placebo in reducing LDL (WMD-0.87, 95%CI -1.18-0.55, P0.0001), TC (WMD-
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1.23 95%CI -1.35-1.11, P0.00001), TG (WMD-0.50, 95%CI -0.73-0.27,
P0.00001); and statinmetforminwasmore effective thanmetformin in lowering
LDL (WMD--0.84, 95%CI: -1.33-0.354, P0.0009), TC (WMD-1.28, 95%CI:
-1.47-1.10 P0.00001), and TG (WMD-0.27, 95%CI: -0.36-0.19, P0.00001). Het-
erogeneities were detected during the meta-analysis. CONCLUSIONS: Statins can
positively reduce the concentration of total testosterone, TC, TG and LDL. It cannot
be concluded, however, that statins have the long-term benefit. A large-scale, well-
designed, randomized controlled study is needed to ascertain this uncertainty.
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OBJECTIVES: To describe characteristics of T2DM patient subgroups who were more
likely to achieve HbA1c goal 7%with combination treatment of DPP4i with PIO orwith
METusingapredictivemodel.METHODS: Stepwise logistic regressionwas applied to
MarketScan claims data to develop a predictive model that estimated the proba-
bilities of HbA1c goal achievement in patients receiving DPP4i combinations. Sam-
ple selection criteria included: 1) T2DM diagnosis; 2) treatment of DPP4i with PIO or
with MET; 3) baseline HbA1c  7%; and 4) with one-year continuous enrollment.
Patients were ranked by the probabilityof achieving HbA1c7% and grouped into
cumulative percentiles; baseline characteristics of the optimal subgroups identi-
fied as the first 20th and 80th percentiles were reported. RESULTS: A total of 328
patients were included. The predictive model showed that patients who had neu-
ropathy, cerebrovascular conditions, or higher total medication use at baseline
were less likely to achieve goal on DPP4i combinations while patients with self
monitoring blood glucose use at baselineweremore likely to achieve goal (P 0.05).
The 80th percentile subgroup (n270) had a goal reaching rate of 57.0%,mean age of
50.3 years old, 44.3% female, 38.5% on MET, 13.8% on thiazolidinedione (TZD), and
HbA1c  9.13% at baseline. The 20th percentile subgroup (n83), achieved goal at
the rate of 72.3%, mean age of 50.6 years old, 46.1% female, 53.9% onMET, 25.7% on
TZD, and HbA1c  8.96% at baseline. CONCLUSIONS: Predictive factors for reaching
goal include: 1) use of self monitoring blood glucose, and 2) lack of neuropathy, cerebro-
vascular disease, or usage of medications. Subgroups that might benefit the most from
DPP4i treatment were identified. These patients exhibited a higher likelihood of having
prior use ofMET or TZD, and baseline HbA1c less than 9.0%.
PDB7
NETWORK META-ANALYSIS OF FIXED DOSE COMBINATION THERAPIES FOR
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OBJECTIVES: To assess the relative efficacy and safety of fixed dose combinations
(FDCs) of anti-diabetic drugs in treatment naïve patients with type 2 diabetes mel-
litus (T2DM) using networkmeta-analysis technique.METHODS: Randomized con-
trolled trials, evaluating FDCs in treatment naïve patients with T2DM were
searched via Embase® and MEDLINE®. The abstracts were reviewed and data ex-
tractions were conducted by two independent reviewers. The outcomes of interest
included reduction in Hb1Ac levels, patients with HbA1c7%, fasting plasma glu-
cose (FPG) levels, and incidence of hypoglycemia. A network meta-analysis using
WinBUGS® was performed to combine the reported direct and indirect evidence
and a probability ranking for the included combinations was generated. RESULTS:
Eleven trials (n5781 patients) comparing the following FDCs: sulfonylureas/bigua-
nides (SUL/BGU), thiazolidinediones/biguanides (TZD/BGU), dipeptidyl peptidase-4
inhibitors/biguanides (DPP-4/BGU), alpha-glucosidase inhibitors/biguanides (AGI/
BGU), and thiazolidinediones/sulfonylureas (TZD/SUL) were included. Following
network meta-analysis using BGU, TZDs, and SUL as common comparators, TZD/
SUL was observed to be significantly better in terms of patients with HbA1c7%
than other FDCs [relative risk; 95% credible intervals vs. SUL/BGU (1.16; 1.03-1.3), vs.
TZD/BGU (1.12; 1.01-1.24), and DPP-4/BGU (1.18; 1.07-1.29)]. Statistically, however,
non-significant differenceswere observed among the FDCs other than TZD/SUL for
this outcome. All FDCs achieved clinically meaningful reductions in HbA1c and
FPG, though the differences between the FDCs were statistically non-significant.
According to the probability ranking for reduction in HbA1c and FPG levels, the
rank favored TZD/SUL followed by AGI/BGU, TZD/BGU, SUL/BGU, and DPP/BGU.
The probability of occurrence of hypoglycemia was highest with SUL/BGU (78.3%)
followed by TZD/SUL (20.2%), TZD/BGU (0.03%), and DPP-4/BGU (0.005%). Incidence
of hypoglycemiawas not reported for AGI/BGU. CONCLUSIONS: Clinically, all FDCs
effectively achieved glycemic control in patients with T2DM, however, the risk
ratios from network meta-analysis were inconclusive to determine the relative
efficacy of these FDCs. The probability ranking suggested the potential use of TZD/
SUL in treatment naïve T2DM patients.
PDB8
BARIATRIC AND METABOLIC SURGERY IN INDIA – EFFICACY AND SAFETY OF
MINIMALLY INVASIVE PROCEDURES
Wojciechowski P1, Metz L2, Mapari J2, Jain M3, Neoh K4, Caban A1, Gaweska M1, Gomulka
A1, Plisko R1, Wladysiuk M1, Rys P1
1HTA Consulting, Krakow, Poland, 2Johnson & Johnson Medical Asia-Pacific, Singapore,
Singapore, 3Johnson & Johnson Medical, New Delhi, India, 4Johnson & Johnson Medical Asia-
Pacific, Petaling Jaya, Malaysia
OBJECTIVES: Obesity and type 2 diabetes mellitus (T2DM) are major health issues
in developing countries contributing to increased morbidity and mortality. Bariat-
ric surgery is an effective procedure leading to durable weight loss in morbidly
obese patients, while metabolic surgery aims at resolving T2DM. The objective of
our study was to assess the efficacy and safety of those procedures in Indians.
METHODS: A comprehensive search was performed in PUBMED and websites of
Indian medical databases and journals (www.indmed.org, www.dmri.in, www.n-
mji.in, www.japi.in). Studiesmet the inclusion criteria if they enrolled Indian obese
patients with or without T2DM undergoing following laparoscopic procedures:
sleeve gastrectomy, Roux-en-Y gastric bypass, adjustable gastric banding, single-
incision sleeve gastrectomy. RESULTS: Our search retrieved nine studies (978 pa-
tients) of which three included T2DM patients (N  91) exclusively. Postoperative
excessive weight loss ranged from 59.1% to 76.1% after 12-months and from 65.2%
to 71.1% after 24-months of follow-up. BMI was reduced by 5.9-20.5 kg/m2, dyslip-
idemia was resolved in 34-100% patients and hypertension was improved in 67-
95% individuals around one year after surgery. Moreover, at the same time joint
pain was reduced in 57-97% patients and sleep apnea in 100% subjects. The inci-
dence of asthma and depression were also reduced following bariatric/metabolic
surgery.Metabolic procedures carried out in the subset of diabeticswere associated
with T2DM resolution in 61-100% of patients, reduction of HbA1c by 2.3-4.0 per-
centage points and improvement in fasting blood glucose by 60-144 mg/dl. Reduc-
tion of BMI among diabetics was in the range between 5.9–9.8 kg/m2. Rates of
postoperative complications were generally low and only one death was reported
due to pulmonary embolism. CONCLUSIONS: Bariatric and metabolic procedures
are effective in both weight reduction as well as improvement or resolution of
T2DM. Those procedures are safe and beneficial in morbidly obese patients espe-
cially with T2DM.
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OBJECTIVES: Many studies have shown the distance from skin to muscle layer is
shorter than imagined; it’s important to ensure insulin injections are consistently
made into subcutaneous layer, without leakage/backflow or subject-reported in-
jection pain. The objective of this study was to assess clinical outcomes in T2DM
patients switched from insulin injection with longer pen needles (PNs) to shorter
PNs. METHODS: A retrospective study was conducted from July ’09 to Jan ’12 to
compare lipohypertrophy, bleeding, bruising, insulin leakage, pain, and bulge on
skin in a clinic in Yilan, Taiwan. Eighty-two patients with diabetes who were pre-
scribed injectable insulin were included. Before Jul ’09, all patients were prescribed
8 mm PNs. There was no limitation of insulin type, dosage, gender or education
level. From July 2009 to August 2011, PN length was switched to 5mm, then (begin-
ning Jul ’11) to 4mm. Injection techniques and injection areas were inspected by
certified diabetes educators every 3 months for all subjects. Standard injection
technique were taught and followed-up in patients. All statistical analyses were
conducted using SAS software (vs. 9.1).RESULTS:Demographic characteristics: age
60.514.3 years, 58.5% males, 92.7% T2DM, diabetes duration 16.07.0 years and
insulin injection duration 6.84.2 years. A1C: 8.31.5%, 8.11.2% and 8.11.1%
(p0.3180); BMI: 25.33.4kg/m2, 25.13.4kg/m2 and 25.435.4kg/m2 (p0.8565).
The bleeding/bruising decreased from 64.6% to 56.1% to 54.9% (p0.0904), lipohy-
pertrophy formation decreased from 26% to 20% to 15% (p 0.1954). Reports of
insulin leakage from tip or skin (p0.8715, 0.5644), pain perception (p0.1379) and
bulge on skin (p0.8039) were not statistically significant between 5mm and 4mm
PNs. CONCLUSIONS: No significant changes in A1C and BMI associated with
change in needle length from 8mm to 5mm and from 5mm to 4mmwere observed.
Therewas no apparent increase in leakage of insulin. A trend towards less bleeding
and pain was observed when using shorter needles.
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OBJECTIVES: Exenatide is a new antidiabetic agent which is an analog of incretin
(glucagon-like peptide 1) with a adjunctive therapy with type 2 diabetes mellitus
(T2DM),and has adverse events of nausea, vomiting and poor appetite. To assess
the clinical efficacy of exenatide in T2DM.METHODS: Inclusion criteria were T2DM
with inadequate glycemic control under oral antidiabetic agnets or insulin therapy.
Exenatide were added on by the reatment course of exenatide is 5g twice a day at
first month and then adjusted to 10g twice a day if tolerated. The primary out-
comes are influence on HbA1C level and body weight. RESULTS: Eighteen patients,
who were 7 male and 11 female with mean age of 43.46, were recruited. Of them
had a mean body weight of 97.15kg and mean HbA1C of 9.1%. HbA1c improved
significantly after 3 months and 6 months with mean reduction of 0.75%(p0.002)
and 0.97%(p0.009). Mean body weight mild decreased at 3 months (4.33 kg) and
reduced significantly at 4 months and 6 months with 5kg (p0.005) and 9.74kg
(p0.0006). CONCLUSIONS: Exenatide improve HbA1c and body weight greatly
within 6months in a local hospital andmayhave great affect on the changing of life
style, like diet control and frequency of Self-Monitoring of Blood Glucose. In future,
a larger and long time study would need to demonstrate the validity of exenatide
on the taiwanese.
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ROLE OF CHROMIUM IN TYPE-2 DIABETES THERAPY: A SYSTEMATIC REVIEW
STUDY
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